Literature DB >> 20689512

In vivo imaging of transgenic Leishmania parasites in a live host.

Colin J Thalhofer1, Joel W Graff, Laurie Love-Homan, Suzanne M Hickerson, Noah Craft, Stephen M Beverley, Mary E Wilson.   

Abstract

Distinct species of Leishmania, a protozoan parasite of the family Trypanosomatidae, typically cause different human disease manifestations. The most common forms of disease are visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). Mouse models of leishmaniasis are widely used, but quantification of parasite burdens during murine disease requires mice to be euthanized at various times after infection. Parasite loads are then measured either by microscopy, limiting dilution assay, or qPCR amplification of parasite DNA. The in vivo imaging system (IVIS) has an integrated software package that allows the detection of a bioluminescent signal associated with cells in living organisms. Both to minimize animal usage and to follow infection longitudinally in individuals, in vivo models for imaging Leishmania spp. causing VL or CL were established. Parasites were engineered to express luciferase, and these were introduced into mice either intradermally or intravenously. Quantitative measurements of the luciferase driving bioluminescence of the transgenic Leishmania parasites within the mouse were made using IVIS. Individual mice can be imaged multiple times during longitudinal studies, allowing us to assess the inter-animal variation in the initial experimental parasite inocula, and to assess the multiplication of parasites in mouse tissues. Parasites are detected with high sensitivity in cutaneous locations. Although it is very likely that the signal (photons/second/parasite) is lower in deeper visceral organs than the skin, but quantitative comparisons of signals in superficial versus deep sites have not been done. It is possible that parasite numbers between body sites cannot be directly compared, although parasite loads in the same tissues can be compared between mice. Examples of one visceralizing species (L. infantum chagasi) and one species causing cutaneous leishmaniasis (L. mexicana) are shown. The IVIS procedure can be used for monitoring and analyzing small animal models of a wide variety of Leishmania species causing the different forms of human leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689512      PMCID: PMC3156083          DOI: 10.3791/1980

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  21 in total

1.  Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major.

Authors:  H R Chakkalath; A A Siddiqui; A H Shankar; D E Dobson; S M Beverley; R G Titus
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Regulation of GP63 mRNA stability in promastigotes of virulent and attenuated Leishmania chagasi.

Authors:  A Brittingham; M A Miller; J E Donelson; M E Wilson
Journal:  Mol Biochem Parasitol       Date:  2001-01-15       Impact factor: 1.759

3.  A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation.

Authors:  G F Späth; S M Beverley
Journal:  Exp Parasitol       Date:  2001-10       Impact factor: 2.011

4.  Identification of an infective stage of Leishmania promastigotes.

Authors:  D L Sacks; P V Perkins
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

5.  Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.

Authors:  P Scott; P Caspar; A Sher
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

6.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation.

Authors:  R da Silva; D L Sacks
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 8.  Imaging Leishmania development in their host cells.

Authors:  Thierry Lang; Hervé Lecoeur; Eric Prina
Journal:  Trends Parasitol       Date:  2009-09-04

9.  The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

Authors:  Y Belkaid; K F Hoffmann; S Mendez; S Kamhawi; M C Udey; T A Wynn; D L Sacks
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  The dynamics of granuloma formation in experimental visceral leishmaniasis.

Authors:  M J McElrath; H W Murray; Z A Cohn
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  30 in total

1.  Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells.

Authors:  Eva Iniguez; Antonio Sánchez; Miguel A Vasquez; Alberto Martínez; Joanna Olivas; Aaron Sattler; Roberto A Sánchez-Delgado; Rosa A Maldonado
Journal:  J Biol Inorg Chem       Date:  2013-07-24       Impact factor: 3.358

2.  Evaluation of α,β-unsaturated ketones as antileishmanial agents.

Authors:  Miguel A Vasquez; Eva Iniguez; Umashankar Das; Stephen M Beverley; Linda J Herrera; Jonathan R Dimmock; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

3.  Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.

Authors:  Alberto Martínez; Teresia Carreon; Eva Iniguez; Atilio Anzellotti; Antonio Sánchez; Marina Tyan; Aaron Sattler; Linda Herrera; Rosa A Maldonado; Roberto A Sánchez-Delgado
Journal:  J Med Chem       Date:  2012-04-09       Impact factor: 7.446

4.  Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney.

Authors:  Lauren E Woodard; Richard C Welch; Felisha M Williams; Wentian Luo; Jizhong Cheng; Matthew H Wilson
Journal:  J Vis Exp       Date:  2018-01-08       Impact factor: 1.355

5.  Different susceptibilities of Leishmania spp. promastigotes to the Annona muricata acetogenins annonacinone and corossolone, and the Platymiscium floribundum coumarin scoparone.

Authors:  Nadja Soares Vila-Nova; Selene Maia de Morais; Maria José Cajazeiras Falcão; Terezinha Thaize Negreiros Alcantara; Pablito Augusto Travassos Ferreira; Eveline Solon Barreira Cavalcanti; Icaro Gusmão Pinto Vieira; Cláudio Cabral Campello; Mary Wilson
Journal:  Exp Parasitol       Date:  2012-12-08       Impact factor: 2.011

6.  Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi.

Authors:  Colin J Thalhofer; Yani Chen; Bayan Sudan; Laurie Love-Homan; Mary E Wilson
Journal:  Infect Immun       Date:  2010-10-11       Impact factor: 3.441

7.  Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.

Authors:  Kevin W Bruhn; Ron Birnbaum; Jacquelyn Haskell; Veena Vanchinathan; Stephanie Greger; Rupa Narayan; Pei-Lin Chang; Thu Anh Tran; Suzanne M Hickerson; Stephen M Beverley; Mary E Wilson; Noah Craft
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

8.  In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors.

Authors:  Felipe Rodriguez; Sarah F John; Eva Iniguez; Sebastian Montalvo; Karina Michael; Lyndsey White; Dong Liang; Omonike A Olaleye; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

9.  Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs.

Authors:  Andrew A Voak; Karin Seifert; Nuala A Helsby; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

10.  Thymol and eugenol derivatives as potential antileishmanial agents.

Authors:  Selene Maia de Morais; Nadja Soares Vila-Nova; Claudia Maria Leal Bevilaqua; Fernanda Cristina Rondon; Carlos Henrique Lobo; Arlindo de Alencar Araripe Noronha Moura; Antônia Débora Sales; Ana Paula Ribeiro Rodrigues; José Ricardo de Figuereido; Claudio Cabral Campello; Mary E Wilson; Heitor Franco de Andrade
Journal:  Bioorg Med Chem       Date:  2014-09-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.